ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 121

Depression As a Risk Factor for the Development of Rheumatoid Arthritis: A Population-Based Cohort Study

Isabelle Vallerand1, Ryan Lewinson2, Mark Lowerison1, Alexandra Frolkis3, Gilaad Kaplan3, Andrew Bulloch4, Scott Patten1 and Cheryl Barnabe5, 1Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 2Biomedical Engineering Program, Schulich School of Engineering, University of Calgary, Calgary, AB, Canada, 3Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 4Department of Physiology & Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, 5Division of Rheumatology, University of Calgary, Calgary, AB, Canada

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Depression and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Epidemiology and Public Health Poster I: Rheumatoid Arthritis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: The underlying risk factors for the development of Rheumatoid Arthritis (RA) remain poorly understood; however, prospective studies have demonstrated that individuals with elevated Tumor Necrosis Factor alpha (TNFα), a pro-inflammatory cytokine, are at increased risk of subsequently developing RA. It remains unknown whether elevated TNFα by means of a different disease process can subsequently increase the risk of developing RA. Recently, major depressive disorder (MDD) has been identified to have a direct effect on cytokines, including increased serum concentrations of TNFα relative to healthy controls independent of underlying inflammatory disease. Based on this, our hypothesis is that exposure to MDD may increase the risk of subsequently developing RA. In this study using a large population-based cohort, we assessed if patients with MDD were at increased risk of subsequently developing RA compared to the general population without MDD.

Methods: A retrospective cohort study was conducted using The Health Improvement Network (THIN) Database between the years 1986-2012 for up to 26 years of follow-up. The MDD cohort comprised patients with a diagnostic (Read) code for MDD and the remainder of patients formed the referent cohort. Both cohorts were followed until patients developed RA or were censored. Cox proportional hazards models were used to determine the risk of developing RA among patients with MDD, as reported using Hazard Ratios (HRs) and 95% confidence intervals (CIs) (α=0.05). A backward elimination procedure was used to determine the presence of effect modification (using a Wald test) or confounding by age or sex.

Results: A cohort of 403,932 patients with MDD and a referent cohort of 5,339,399 patients without MDD were identified in THIN. A total of 2,192 (0.54%) patients with MDD developed RA, and 24,021 (0.45%) patients without MDD developed RA over this period. Cox proportional hazards models identified a confounding effect by sex and a significant interaction by age (p<0.0001), whereby younger patients with MDD (age<40) had a 42% increased risk of developing RA (sex-adjusted HR=1.42, 95%CI: 1.31 – 1.53). In older patients (age>40), the risk of developing RA among those with MDD was lower but demonstrated a 14% increased risk (sex-adjusted HR=1.14, 95%CI: 1.08-1.21).

Conclusion: MDD was found to be a risk factor for the development of RA. This risk was highest among younger patients with MDD, and the risk was only somewhat increased among older patients with MDD. These results provide support the hypothesis that MDD may be associated with the development of RA.


Disclosure: I. Vallerand, Canadian Rheumatology Association and Novartis, 3; R. Lewinson, None; M. Lowerison, None; A. Frolkis, None; G. Kaplan, None; A. Bulloch, None; S. Patten, None; C. Barnabe, None.

To cite this abstract in AMA style:

Vallerand I, Lewinson R, Lowerison M, Frolkis A, Kaplan G, Bulloch A, Patten S, Barnabe C. Depression As a Risk Factor for the Development of Rheumatoid Arthritis: A Population-Based Cohort Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/depression-as-a-risk-factor-for-the-development-of-rheumatoid-arthritis-a-population-based-cohort-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/depression-as-a-risk-factor-for-the-development-of-rheumatoid-arthritis-a-population-based-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology